Burning Rock Announces Results of 2024 Annual General Meeting
Burning Rock Biotech (NASDAQ: BNR), a company specializing in NGS technology for precision oncology, announced that all resolutions proposed at its 2024 annual general meeting were approved by shareholders. The key resolutions included: the ratification of Ernst & Young Hua Ming LLP as the company's auditor for fiscal year 2024, the re-election of directors Yusheng Han and Gang Lu, and the authorization for directors to implement these resolutions at their discretion.
Burning Rock Biotech (NASDAQ: BNR), un'azienda specializzata nella tecnologia NGS per l'oncologia di precisione, ha annunciato che tutte le delibere proposte durante l'assemblea generale annuale del 2024 sono state approvate dagli azionisti. Le principali delibere includevano: la ratifica di Ernst & Young Hua Ming LLP come revisore dei conti dell'azienda per l'esercizio fiscale 2024, la rielezione dei direttori Yusheng Han e Gang Lu, e l'autorizzazione ai direttori di attuare queste delibere a loro discrezione.
Burning Rock Biotech (NASDAQ: BNR), una empresa especializada en tecnología NGS para oncología de precisión, anunció que todas las resoluciones propuestas en su reunión general anual de 2024 fueron aprobadas por los accionistas. Las resoluciones clave incluyeron: la ratificación de Ernst & Young Hua Ming LLP como auditor de la empresa para el año fiscal 2024, la reelección de los directores Yusheng Han y Gang Lu, y la autorización para que los directores implementen estas resoluciones a su discreción.
Burning Rock Biotech (NASDAQ: BNR)는 정밀 종양학을 위한 NGS 기술을 전문으로 하는 회사로, 2024년 연례 총회에서 제안된 모든 결의안이 주주들에 의해 승인되었음을 발표했습니다. 주요 결의안에는 2024 회계연도 동안 회사의 감사인으로 Ernst & Young Hua Ming LLP의 승인, 이사 Yusheng Han과 Gang Lu의 재선이 포함되었으며, 이사들이 이러한 결의안을 재량에 따라 시행할 수 있도록 권한을 부여하는 내용이 포함되었습니다.
Burning Rock Biotech (NASDAQ: BNR), une entreprise spécialisée dans la technologie NGS pour l'oncologie de précision, a annoncé que toutes les résolutions proposées lors de son assemblée générale annuelle de 2024 ont été approuvées par les actionnaires. Les principales résolutions comprenaient : la ratification de Ernst & Young Hua Ming LLP en tant qu'auditeur de l'entreprise pour l'exercice fiscal 2024, la réélection des administrateurs Yusheng Han et Gang Lu, et l'autorisation pour les administrateurs de mettre en œuvre ces résolutions à leur discrétion.
Burning Rock Biotech (NASDAQ: BNR), ein Unternehmen, das sich auf NGS-Technologie für präzise Onkologie spezialisiert hat, gab bekannt, dass alle bei der Hauptversammlung 2024 vorgeschlagenen Beschlüsse von den Aktionären genehmigt wurden. Die wichtigsten Beschlüsse umfassten: die Bestätigung von Ernst & Young Hua Ming LLP als Wirtschaftsprüfer des Unternehmens für das Haushaltsjahr 2024, die Wiederwahl der Direktoren Yusheng Han und Gang Lu, sowie die Ermächtigung der Direktoren, diese Beschlüsse nach ihrem Ermessen umzusetzen.
- None.
- None.
GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company’s 2024 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions:
- as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2024 be ratified and that the directors of the Company be authorized to determine the remuneration of the auditor;
- as an ordinary resolution, THAT Yusheng Han and Gang Lu be re-elected as directors of the Company; and
- as an ordinary resolution, THAT each of the directors of the Company be authorized to take any and all action that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
For more information about Burning Rock, please visit: ir.brbiotech.com.
Contact: IR@brbiotech.com
FAQ
What resolutions were passed at Burning Rock's (BNR) 2024 annual general meeting?
Who was appointed as Burning Rock's (BNR) auditor for fiscal year 2024?
Which directors were re-elected to Burning Rock's (BNR) board in 2024?
What type of company is Burning Rock (BNR) and what is their main focus?
